Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 273

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 273
---
 make significant changes to the recognition, measurement, and presentation of
expenses and cash flows by a Lessee.

Effective January 1, 2022, the Company
adopted the new lease accounting standard. The Company elected to apply the practical expedients permitted under the transition guidance
within the new standard. As such, there was no impact on the Company’s financial statements as a result of adopting ASU 2016-02.

<div align='center'>F-27</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |

Effective January 1, 2023, the Company
adopted ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset
measured at amortized cost to be presented at the net amount expected to be collected. There was no impact on the Company’s financial
statements as a result of adopting ASU 2016-13.

| o. | Accounting pronouncement not yet adopted |

As an “emerging growth company”,
the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflect this election.

In August 2020, the FASB issued ASU No.
2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies
the accounting for certain convertible instruments, amends the guidance on derivative scope exceptions for contracts in an entity’s
own equity, and modifies the guidance on diluted earnings per share calculations as a result of these changes. The guidance is effective
for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. The Company is currently evaluating
the effect of adopting the ASU on its disclosures.

In December 2023, the FASB issued ASU
No. 2023-09, Income Tax (Topic 740): Improvements to Income Tax Disclosures, which amended disclosure requirements for income